Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Anthraquinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.92 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.73 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.92 |
| ▸ | CDC25B | P30305 | 3/20 | 0.92 |
| ▸ | MAOA | P21397 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | APAF1 | O14727 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | TDP2 | O95551 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | S100A4 | P26447 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | CES2 | O00748 | 1/20 | 0.73 |
| ▸ | TERT | O14746 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthraquinone SCHEMBL6415478 | 1.00 | MEN1 (0.92) | MEN1KMT2ACDC25BMAOARAB9A | |
| Anthraquinone SCHEMBL28104615 | 1.00 | MEN1 (0.92) | MEN1KMT2ACDC25BMAOARAB9A | |
| Anthraquinone SCHEMBL30692662 | 1.00 | MEN1 (0.92) | MEN1KMT2ACDC25BMAOARAB9A | |
| Anthraquinone SCHEMBL27288066 | 0.96 | MEN1 (0.86) | MEN1KMT2ACDC25BMAOARAB9A | |
| Anthraquinone SCHEMBL28335026 | 0.96 | MEN1 (0.86) | MEN1KMT2ACDC25BMAOARAB9A | |
| Water SCHEMBL7789828 | 0.96 | MEN1 (0.86) | MEN1KMT2ACDC25BMAOARAB9A | |
| Anthraquinone SCHEMBL28192712 | 0.96 | MEN1 (0.86) | MEN1KMT2ACDC25BMAOARAB9A | |
| Anthraquinone SCHEMBL1901249 | 0.96 | MEN1 (1.00) | MEN1KMT2ACDC25BMAOARAB9A | |
| Anthraquinone SCHEMBL29358690 | 0.96 | MEN1 (1.00) | MEN1KMT2ACDC25BMAOARAB9A | |
| Anthraquinone SCHEMBL14943 | 0.96 | MEN1 (1.00) | MEN1KMT2ACDC25BMAOARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1504453-A | 1, 5-disubstituted anthraquinone derivative and synthesis method and application thereof | 黄旭山 | 2004-06-16 | — | — | CN | claimed |
| EP-4688910-A1 | POLYESTER (METH)ACRYLATE, METHOD FOR PREPARING SAME AND USES THEREOF | ARKEMA France (FR) | 2026-02-11 | — | — | EP | disclosed |
| CN-120192489-A | A-D-A type COF photocatalyst and preparation method and application thereof | 南京师范大学 | 2025-06-24 | — | — | CN | disclosed |
| WO-2024200250-A1 | POLYESTER (METH)ACRYLATE, METHOD FOR PREPARING SAME AND USES THEREOF | ARKEMA FRANCE (FR) | 2024-10-03 | — | — | WO | disclosed |
| CN-209338117-U | A kind of dioxygen water preparation apparatus | 江苏德邦工程有限公司 | 2019-09-03 | — | — | CN | disclosed |
| CN-106179427-B | A kind of efficient and long life regenerating anthraquinone degradation products catalyst and preparation method thereof | 江苏晶晶新材料有限公司 | 2019-06-18 | — | — | CN | disclosed |
| CN-109620865-A | A kind of Shengxuebao-medicine for improving hematopoitic function particle and preparation method thereof for being easy to absorb | 谈发金 | 2019-04-16 | — | — | CN | disclosed |
| CN-109568395-A | A kind of preparation method of polygonum cuspidate granule | 广东方制药有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-108862205-A | A kind of dioxygen water preparation apparatus | 江苏德邦工程有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-106179427-A | A kind of novel high-efficiency long-life regenerating anthraquinone degradation products catalyst and preparation method thereof | 江苏晶晶新材料有限公司 | 2016-12-07 | — | — | CN | disclosed |
| CN-1826098-A | Production of small particles | APPLIED NANOSYSTEMS BV (NL) | 2006-08-30 | — | — | CN | disclosed |
| CN-1504453-A | 1, 5-disubstituted anthraquinone derivative and synthesis method and application thereof | 黄旭山 | 2004-06-16 | — | — | CN | disclosed |
| US-5476863-A | Inhibitors of platelet activating factor and diseases caused thereby; stability | EISAI CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5476864-A | Therapy for diseases caused by platelet activation factor | EISAI CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| EP-0353474-B1 | Glycerin derivative and its pharmacological use | EISAI CO LTD (JP) | 1995-04-05 | — | — | EP | disclosed |
| EP-0399985-B1 | Process for producing N-phosphonomethylglycine | MONSANTO CO (US) | 1995-01-04 | — | — | EP | disclosed |
| US-5037827-A | Useful for treatment of disease caused by platelet activating factory | EISAI CO., LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0399985-A2 | Process for producing N-phosphonomethylglycine | MONSANTO COMPANY (US) | 1990-11-28 | — | — | EP | disclosed |
| CN-1005911-B | Method for producing hydrogen peroxide | 福来特S·A | 1989-11-29 | — | — | CN | disclosed |
| CN-86100770-A | Method for producing hydrogen peroxide | — | 1987-08-05 | — | — | CN | disclosed |